Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

53.09 +0.21 (+0.41%)
Streaming Delayed Price Updated: 12:20 PM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,528,889
Open 52.71
Bid (Size) 53.09 (2)
Ask (Size) 53.10 (9)
Prev. Close 52.88
Today's Range 52.71 - 53.61
52wk Range 38.48 - 61.71
Shares Outstanding 5,606,688,356
Dividend Yield 2.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies
 
Via Benzinga
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
The company is planning to soon ask for FDA approval of etrasimod in ulcerative colitis. 
Via Investor's Business Daily

Performance

YTD
-6.28%
-6.28%
1 Month
+8.47%
+8.47%
3 Month
+11.71%
+11.71%
6 Month
+3.70%
+3.70%
1 Year
+33.37%
+33.37%

More News

Read More
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma
Via Benzinga
S&P 500 1Q22 Earnings Recap: Growth Holding Up
Via Talk Markets
Pfizer, NIH Mulling Study For Longer Paxlovid Course To Combat Reinfections
Via Benzinga
Read Why Pfizer Is Limiting Supply Of Paxlovid For Combination Studies: Bloomberg
Via Benzinga
Amid Monkeypox Outbreak, This 3X Leveraged ETF Provides Exposure To Health Sector: What To Watch
Via Benzinga
Pfizer, BioNTech Say Three-Dose Covid Vaccine Is 80% Effective In Children Under 5
Via Investor's Business Daily
Morning Brief: Top Financial Stories Dominating on Monday, May 23
Via Benzinga
European Regulator Approves AstraZeneca's COVID-19 shot As Booster
Via Benzinga
Pfizer-BioNTech's Third COVID-19 Vaccine Shot Shows 80% Efficacy In Youngest Children
Via Benzinga
Texas Pfizer Covid/Nursing 2022 Scholarship | Minority Student Grants Announced
Via Press Release Distribution Service
Exposures COVID-19
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
From Pfizer Inc.
Via Business Wire
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
Online shop Etalaze announces shift to a new domain www.Etalaze.biz
Via AB Newswire
Mystery Solved! The Top 9 Bestselling Products In History
Via Benzinga
This Is What Whales Are Betting On Pfizer
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, May 20
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
CDC Recommends Pfizer/BioNTech COVID-19 Booster Shots For Kids Aged 5-11 Years
Via Benzinga
5 Oversold Blue-Chip Stocks to Buy Right Now
Via InvestorPlace
North Carolina Physicians' Group Calls for Halt to Atrium COVID Vaccine Trial for Children
Via Newswire.com
Topics Death
Exposures COVID-19 Death
Upcoming U.S. FDA Decision A Potentially Major De-Risk Event For Revive Therapeutics
Via Benzinga
Looking At Pfizer's Recent Whale Trades
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.